Matthias Hackl, CEO/CSO of TAmiRNA, visited Japan between November 11th and 18th to join Summit Pharmaceutical international to introduce TAmiRNA to 12 medium- and large-size pharmaceutical companies. Matthias presented information on microRNA and mRNA biomarker discovery in liquid biopsies using TAmiRNA´s unique miND® pipeline for absolute quantification of microRNAs. In addition, Matthias joined a seminar on “Manufacturing and omic-based characterization of extracellular vesicles as drug products” organized by the local partner Summit Pharmaceutical International. In his talk, Matthias explained to >70 representatives from Japanese Universities and Pharmaceutical industry TAmiRNA’s the advantages of full molecular characterization of exosomes and extracellular vesicles (EVs) to determine EV composition, consistency, and mode-of-action.
We want to draw your attention to our latest publication which appeared in American Journal of Physiology-Renal Physiology. We could show that laser microdissection combined with (small) RNA sequencing revealed renal microvascular compartment-specific miRNA and mRNA expression profiles. Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney Luxen M, Zwiers PJ, Meester F et al. Am J Physiol Renal Physiol. 2023 Sep 1;325(3):F299-F316. doi: 10.1152/ajprenal.00005.2023. Epub 2023 Jul 6. TAmiRNA and Dutch company Vivomicx have combined their respective technologies of high sensitivity gene expression profiling (RT-qPCR and smallRNAseq/RNAseq) and laser microdissection to enable cell-type specific and space-resolved RNA expression analysis in complex tissues. Click here to learn more about this service
The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To overcome this problem, Michael and his team, developed a set of synthetic small RNA Spike-Ins that could be added to these tissue samples. This technology allows us to accurately quantify the levels of different small RNAs that could play a role in several human diseases, ranging from cancer to cardiovascular disease. In 2019, GMI [...]
Ask the Expert: kit or service, NGS or qPCR – what is the best choice for my microRNA biomarker project?
Can't find the answer to your question on our site? Not sure which method is right for your research? Get in touch with our experts at TAmiRNA - they will answer your questions and help to move from your ideas to results. Get in touch